Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Erica L. Mayer, M.D.

Co-Author

This page shows the publications co-authored by Erica Mayer and Rebecca Gelman.
Connection Strength

0.416
  1. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78.
    View in: PubMed
    Score: 0.129
  2. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23.
    View in: PubMed
    Score: 0.101
  3. Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10564.
    View in: PubMed
    Score: 0.083
  4. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
    View in: PubMed
    Score: 0.035
  5. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7.
    View in: PubMed
    Score: 0.034
  6. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.